SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ljungberg B, Hanbury DC, Kuczyk MA et al. Renal cell carcinoma guideline. Eur Urol 2007; 51: 150210
  • 2
    Kruck S, Merseburger AS, Gakis G, Kramer MW, Stenzl A, Kuczyk MA. An update on the medical therapy of advanced metastatic renal cell carcinoma. Scand J Urol Nephrol 2008; 42: 5016
  • 3
    He Q, Fornander T, Johansson H et al. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res 2006; 26: 47539
  • 4
    He E, Xu XH, Guan H et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma. Nucleosides Nucleotides Nucleic Acids 2010; 29: 3528
  • 5
    Svobodova S, Topolcan O, Holubec L et al. Prognostic importance of thymidine kinase in colorectal and breast cancer. Anticancer Res 2007; 27: 19079
  • 6
    Gronowitz JS, Steinholtz L, Kallander CF, Hagberg H, Bergh J. Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis, and other biochemical markers. Cancer 1986; 58: 1118
  • 7
    Zhang J, Jia Q, Zou S et al. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep 2006; 15: 45561
  • 8
    Mizutani Y, Wada H, Yoshida O, Fukushima M, Nakao M, Miki T. Significance of thymidine kinase activity in renal cell carcinoma. J Urol 2003; 169: 7069
  • 9
    Luo P, Wang N, He E et al. The proliferation marker thymidine kinase 1 level is high in normal kidney tubule cells compared to other normal and malignant renal cells. Pathol Oncol Res 2010; 16: 27783
  • 10
    Ke PY, Chang ZF. Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway. Mol Cell Biol 2004; 24: 51426
  • 11
    Gakis G, Hennenlotter J, Scharpf M et al. XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma. World J Urol 2010; [Epub ahead of print]. DOI: 10.1007/s00345-010-0621-8
  • 12
    Vogel UF, Bueltmann BD. Simple, inexpensive, and precise paraffin tissue microarrays constructed with a conventional microcompound table and a drill grinder. Am J Clin Pathol 2006; 126: 3428
  • 13
    Vogel UF. Combining different techniques to construct paraffin tissue microarrays of superior quality. Histopathology 2009; 54: 6246
  • 14
    Chen Y, Ying M, Hu M et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings. Int J Clin Oncol 2010; 15: 35968
  • 15
    Konoplev SN, Fritsche HA, O'Brien S et al. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. Am J Clin Pathol 2010; 134: 4727
  • 16
    Chen Z, Zhou H, Li S et al. Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours. Anticancer Res 2008; 28: 3897907
  • 17
    Nisman B, Yutkin V, Nechushtan H et al. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy. Urology 2010; 76: 513 e16
  • 18
    Luo P, He E, Eriksson S et al. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker. Eur J Cancer Prev 2009; 18: 2204
  • 19
    He Q, Zhang P, Zou L et al. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep 2005; 14: 10139
  • 20
    Wu C, Yang R, Zhou J et al. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods 2003; 277: 15769
  • 21
    Kuroiwa N, Nakayama M, Fukuda T et al. Specific recognition of cytosolic thymidine kinase in the human lung tumor by monoclonal antibodies raised against recombinant human thymidine kinase. J Immunol Methods 2001; 253: 111
  • 22
    He Q, Skog S, Wang N, Eriksson S, Tribukait B. Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Eur J Cell Biol 1996; 70: 11724
  • 23
    Wang N, He Q, Skog S, Eriksson S, Tribukait B. Investigation on cell proliferation with a new antibody against thymidine kinase 1. Anal Cell Pathol 2001; 23: 119
  • 24
    Mao Y, Wu J, Wang N et al. A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer. Cancer Invest 2002; 20: 92231